Articles tagged "Hepatitis"

2019 American Transplant Congress
HOPE in Action: A Multicenter Prospective Study of HIV to HIV Liver Transplantation
C. Durand¹, S. Florman², M. Bowring³, D. Brown¹, B. Haydel², J. Hamilton¹, P. Stock⁴, J. Price⁵, T. Pruett⁶, V. Kirchner⁷, D. Wojciechowksi⁸, N. Turgeon⁹, C. Wolfe¹⁰, V. Stosor¹¹, J. Charette¹¹, A. Cameron³, S. Ottmann³, S. Huprikar¹², D. Segev³
¹Medicine, Johns Hopkins University, Baltimore, MD, ²Surgery, Mount Sinai, New York, NY, ³Surgery, Johns Hopkins University, Baltimore, MD, ⁴Surgery, University of California San Francisco, San Francisco, CA, ⁵Medicine, University of California San Francisco, San Francisco, CA, ⁶Surgery, University of Minnesota, Minneapolis, MN, ⁷Medicine, University of Minnesota, Minneapolis, MN, ⁸Medicine, Mass General Hospital, Boston, MA, ⁹Surgery, Emory University, Atlanta, GA, ¹⁰Medicine, Duke University, Durham, NC, ¹¹Medicine, Northwestern University, Chicago, IL, ¹²Medicine, Mount Sinai, New York, NY
*Purpose: HIV+ liver transplant (LT) candidates face higher mortality and lower access to transplant compared to HIV- counterparts. With the US HOPE Act, HIV+ donor…
2018 American Transplant Congress
Impact of Early Corticosteroid Treatment in Patients with Indeterminate Acute Severe Hepatitis
E. Mohr,¹ R. Sucher,² T. Müller,³ T. Kaiser,⁴ T. Berg.¹
¹Hepatology, University Clinic Leipzig, Leipzig, Germany; ²Transplant Surgery, University Clinic Leipzig, Leipzig, Germany; ³Hepatology, Charite, Berliin, Germany; ⁴Laboratory Diagnostics, University Clinic Leipzig, Leipzig, Germany.
Background and Aims: Discrimination of acute severe autoimmune hepatitis AIH and drug induced liver injury in patients with indeterminate acute severe Hepatitis is challenging. Early…
2017 American Transplant Congress
Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study.
O. Marion,¹ F. Abravanel,² L. Esposito,¹ S. Lhomme,² A. Del Bello,¹ J. Izopet,² N. Kamar.¹
¹Nephrology and Organ Transplant Unit, CHU Rangueil, Toulouse, France; ²Laboratory of Virology, CHU Purpan, Toulouse, France
Hepatitis E virus (HEV) is responsible for acute and chronic autochthonous hepatitis in developed countries, particularly in Western Europe. Conversely to hepatitis B or C,…
2017 American Transplant Congress
Risk Factor for Hepatitis E Virus Infection Among Solid-Organ-Transplant Patients.
N. Kamar,¹ S. Lhomme,² F. Abravanel,² L. Esposito,¹ A. Hebral,¹ O. Marion,¹ A. Del Bello,¹ J. Izopet.²
¹Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France; ²Department of Virology, Toulouse University Hospital, Toulouse, France
Genotype 3 and 4 hepatitis E virus (HEV) infections are prevalent in developed countries and can cause chronic hepatitis, cirrhosis, and extra-hepatic manifestations among solid-organ-transplant…
2016 American Transplant Congress
Review of Organ Utilization from Increased Infectious Risk Donors.
A. L'Huillier,¹ A. Humar,² C. Payne,³ D. Kumar.²
¹Division of Infectious Diseases, Hospital for Sick Children and University of Toronto, Toronto, Canada; ²Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, Canada; ³Trillium Gift of Life Network, Toronto, Canada.
IntroductionDonors with an increased risk of transmitting HIV, HBV or HCV (IRDs) are a potential source of organs. There is a lack of data on…
2016 American Transplant Congress
Long Term Outcome of De-Novo Autoimmune Hepatitis in Pediatric Recipients of Liver Transplantation.
Y. Avitzur,¹ P. McKiernan,² M. Martinez,³ S. Lobritto,³ D. Kelly,² V. Ng,¹ E. Alonso,⁴ U. Ekong.⁵
¹Hospital for Sick Children, Toronto, Canada; ²Birmingham Children's Hospital, Birmingham, United Kingdom; ³Morgan Stanley Children's Hospital, New York; ⁴Lurie Children's Hospital, Chicago; ⁵Yale New Haven Children's Hospital, New Haven.
Background: De-novo autoimmune hepatitis (DAIH) is a chronic immune mediated graft disorder seen following liver transplantation (LT). The long-term course and outcome of DAIH is…
2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
S. Pol,¹ A. Aghemo,² L. Lin,³ R. Hyland,³ C. Yun,³ J. Spellman,³ M. Natha,³ D. Brainard,³ J. McHutchison,³ M. Bourlière,⁴ M. Peck-Radosavljevic,⁶ M. Michael,⁵ M. Colombo.²
¹Hopital Cochin, Paris, France; ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³Gilead Sciences Inc, Foster City; ⁴Hôpital Saint Joseph, Marseilles, France; ⁵Hannover Medical School, Hannover, Germany; ⁶Medical University of Vienna, Vienna, Austria.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…
2015 American Transplant Congress
The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis
S. Munoz,¹ D. Reich,² K. Rothstein.¹
¹Div of Hepatology, Liver Failure Unit, Hanemann University Hospital, Philadelphia, PA; ²Liver, Kidney and Pancreas Transplant Program, Hahnemann University Hospital, Philadelphia, PA.
The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective…